Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients
April 15 2019 - 7:00AM
Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a
clinical-stage immuno-oncology company developing innovative
therapies for the treatment of cancer, today announced the
publication of data highlighting the role of TTI-621 in treating
patients with Sézary syndrome (SS), a form of cutaneous T-cell
lymphoma (CTCL).
The paper titled “Targeting CD47 in Sézary
syndrome with SIRPαFc”, published in the April 9th issue of Blood
Advances, demonstrates that TTI-621 (SIRPα-IgG1 Fc) triggers
macrophage-mediated phagocytosis of Sézary cells and reduces tumor
load in SS patients following intravenous administration. Four of
five heavily pre-treated SS patients had a decrease in the dominant
malignant clone and other markers of tumor burden after a single
infusion of TTI-621. “We continue to be excited by the monotherapy
data emerging from our TTI-621 clinical studies,” stated Dr. Niclas
Stiernholm, president and CEO of Trillium Therapeutics. “The
results in this manuscript provide further support for
investigating the therapeutic potential of our novel CD47-blocking
agent in CTCL patients.”
About Trillium Therapeutics:
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target CD47,
a “do not eat” signal that cancer cells frequently use to evade the
immune system. Trillium also has a preclinical STING program and a
proprietary fluorine-based medicinal chemistry platform that is
being used to develop novel compounds directed at undisclosed
immuno-oncology targets.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). Forward-looking statements in this press release
include our belief that monotherapy data emerging from our clinical
studies are favorable and support further investigation. With
respect to the forward-looking statements contained in this press
release, Trillium has made numerous assumptions regarding, among
other things: the effectiveness of preclinical trials; and the
completeness, accuracy and usefulness of the data. A more complete
discussion of the risks and uncertainties facing Trillium appears
in Trillium's Annual Information Form for the year ended December
31, 2018 filed with Canadian securities authorities and available
at www.sedar.com and on Form 20-F with the U.S. Securities Exchange
Commission and available at www.sec.gov, each as updated by
Trillium's continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Trillium disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Investor Relations:James
ParsonsChief Financial OfficerTrillium Therapeutics
Inc.416-595-0627 x232james@trilliumtherapeutics.com
Media Relations:Jessica
TieszenCanale Communications for Trillium
Therapeutics619-849-5385jessica@canalecomm.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Apr 2024 to May 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From May 2023 to May 2024